Skip to main content

Advertisement

Log in

Cancer

Indeterminate thyroid nodules—added testing, added value?

  • News & Views
  • Published:

From Nature Reviews Endocrinology

View current issue Sign up to alerts

Combination of the gene-expression classifier (GEC), with its high negative predictive value, and the BRAF mutation test, with its high specificity, might have a synergistic effect in the diagnosis of thyroid nodules with indeterminate cytology. However, Kloos et al. demonstrate that the BRAF test is of no additional benefit in nodules categorized as 'benign' by GEC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Baloch, Z. W. et al. Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn. Cytopathol. 36, 425–437 (2008).

    Article  Google Scholar 

  2. Cooper, D. S. et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19, 1167–1214 (2009).

    Article  Google Scholar 

  3. Alexander, E. K. et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N. Engl. J. Med. 367, 705–715 (2012).

    Article  CAS  Google Scholar 

  4. Nikiforov, Y. E. et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J. Clin. Endocrinol. Metab. 96, 3390–3397 (2011).

    Article  CAS  Google Scholar 

  5. Keutgen, X. M. et al. A panel of four miRNAs accurately differentiates malignant from benign indeterminate thyroid lesions on fine needle aspiration. Clin. Cancer Res. 18, 2032–2038 (2012).

    Article  CAS  Google Scholar 

  6. Kloos, R. T. et al. Does addition of BRAF V600E Mutation testing modify sensitivity or specificity of the Afirma gene expression classifier in cytologically indeterminate thyroid nodules? J. Clin. Endocrinol. Metab. http://dx.doi.org/10.1210/jc.2012-3762

  7. Kimura, E. T. et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC–RAS–BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 63, 1454–1457 (2003).

    CAS  PubMed  Google Scholar 

  8. Kwak, J. Y. et al. How to combine ultrasound and cytological information in decision making about thyroid nodules. Eur. Radiol. 19, 1923–1931 (2009).

    Article  Google Scholar 

  9. Lee, S. W. et al. Combined categorical reporting systems of US and cytology findings for thyroid nodules: guidance on repeat fine-needle aspiration cytology. Radiology 266, 956–963 (2013).

    Article  Google Scholar 

  10. Cantisani, V. et al. Q-elastography in the presurgical diagnosis of thyroid nodules with indeterminate cytology. PLoS ONE 7, e50725 (2012).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kwak, J., Kim, EK. Indeterminate thyroid nodules—added testing, added value?. Nat Rev Endocrinol 9, 321–323 (2013). https://doi.org/10.1038/nrendo.2013.79

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrendo.2013.79

  • Springer Nature Limited

This article is cited by

Navigation